Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab

Gastrointestinal Cancer

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab

Eur J Cancer

Casadei-Gardini A, Yip TC, Vitale A, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Scartozzi M, Tamburini E, Foschi FG, Camera S, Persano M, Pia D'Agata A, Ferrara M, Passeri L, Rimassa L, Rimini M

doi: 10.1016/j.ejca.2026.116750

Gastrointestinal Cancer

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Eur J Cancer

Vo-Quang E, Campani C, Allaire M, Bouattour M, Regnault H, Marra F, Sutter O, Leroy V, Trepo E, Mouri S, Thabut D, Ozenne V, Sidali S, Hollande C, Boros C, Nahon P, Ganne-Carrié N, Lequoy M, Amaddeo G, Nault JC, Paris Liver Cancer Group

doi: 10.1016/j.ejca.2026.116704

ELCC 2026

Lung, Respiratory and Thoracic Cancer

LBA1: LATIFY: No survival benefit with ceralasertib plus durvalumab versus docetaxel in patients with previously treated advanced NSCLC

Lung, Respiratory and Thoracic Cancer

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

Clin Transl Radiat Oncol

Filippi AR, Bar J, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Van Den Heuvel MM, Vercauter P, Smit HJM, Solomon B, Chander P, Qiao Y, Faria J, Girard N

doi: 10.1016/j.ctro.2026.101138

ESMO 2026

Genitourinary Cancer

LBA2: VOLGA: Perioperative durvalumab plus enfortumab vedotin significantly improves EFS and OS in patients with MIBC

Gynecologic Cancer

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

Ann Oncol

Harter P, Trillsch F, Okamoto A, Reuss A, Kim JW, Rubio-Pérez MJ, Vardar MA, Scambia G, Trédan O, Nyvang GB, Colombo N, Bidziński M, Grimm C, Lheureux S, Van Nieuwenhuysen E, Heitz F, Wenham RM, Nishio S, Lim MC, Marquina G, Altundağ Ö, Bergamini A, Sabatier R, Wimberger P, Gold MA, Sehouli J, Park-Simon TW, Kent E, Correa A, Aghajanian C, DUO-O Investigators

doi: 10.1016/j.annonc.2025.11.020

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

CHICAGO 2026

Genitourinary Cancer

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC

ASH 2025

Lymphoma

Related content

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

LBA1: LATIFY: No survival benefit with ceralasertib plus durvalumab versus docetaxel in patients with previously treated advanced NSCLC

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

LBA2: VOLGA: Perioperative durvalumab plus enfortumab vedotin significantly improves EFS and OS in patients with MIBC

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab